Work

Enhancing Facial Rejuvenation Outcomes With a Novel Retinaldehyde‐Based Cream: A Comparative Randomized Intra‐Individual Study

Year: 2025
Type: article
Abstract: BACKGROUND: Minimally-to-moderately invasive facial rejuvenation procedures, such as chemical peels, hyaluronic acid (HA) injections and fractional lasers, yield visible improvements in skin texture, tone and wrinkles; their long-term benefits can be optimized through a targeted anti-aging skincare regimen. AIMS: This controlled study aimed to evaluate the tolerability and efficacy of a cream containing three evidence-based active ingredients (retinaldehyde, niacinamide and haritaki fruit extract) to support and maintain the benefits of minimally to moderately invasive facial rejuvenation procedures. METHODS: A monocentric, controlled, randomized, split-face study was conducted over a three-month period in subjects who had undergone one type of rejuvenation procedure, with assessments beginning after re-epidermization. Subjects were instructed to apply the test product on the randomized hemiface once daily. RESULTS: This comparative controlled study, conducted under close dermatological supervision in 66 subjects who had undergone either chemical peels, HA injections, or fractional laser (n = 22 per group), demonstrated that the cream significantly improved multiple signs of aging. Throughout the entire study, compliance was very good. At 1 month (M1), wrinkles were significantly reduced, and the skin was significantly firmer and plumper, with improved texture. Skin tone homogeneity and radiance were significantly enhanced as of M1 (and M2 for skin smoothness) versus the control hemiface. CONCLUSION: Regular application of the study product, which contains retinaldehyde, niacinamide, and haritaki fruit extract, yielded significantly visible anti-aging results already at 1 month compared with the control, with very good skin tolerance. It can be used to maximize and maintain the benefits of rejuvenation procedures and promote long-term skin health. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06942403.
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,020
OpenAlex ID: W4416780561
FWCI: 1.642
Cites: 19
Cited by: 2
Related to: